ReviewThe oncologist2018
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
Review in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Efficacy in patients withFuture oncology (London, England) · 2024Trial
- Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Long-Term Cutaneous Hyperpigmentation During Adjuvant Osimertinib Therapy in a Resected Stage IIB EGFR L858R-Mutated Lung Adenocarcinoma in an Older Adult: A Rare Case Report with Two-Year Follow-Up and Literature Review.Current oncology (Toronto, Ont.) · 2026Review
- [(Bromomethyl)phenyl]methyl-Conjugated Chalcone Derivatives as Potential Lung Cancer Inhibitors: Structure Modification, Molecular Docking, Molecular Dynamics and In Vitro Validation.International journal of molecular sciences · 2026Article
- Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Osimertinib, a Trigger of Subacute Cutaneous Lupus Erythematosus: Three-Patient Case Series and Literature Review.Clinical, cosmetic and investigational dermatology · 2026Article
- Dermatologic Adverse Event Mitigation and Management Strategies with Amivantamab + Lazertinib Therapy for Advanced Non-Small Cell Lung Cancer: A Vodcast.Targeted oncology · 2025Article
- Outcome measures reported by cancer patients treated with tyrosine kinase inhibitors: a methodological study.Revista brasileira de enfermagem · 2025Article
- Drug-induced subacute cutaneous lupus erythematosus involving osimertinib.JAAD case reports · 2024Article
- Subacute cutaneous lupus erythematosus following osimertinib therapy for non-small cell lung cancer: A case report.JAAD case reports · 2024Article
- Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients.Acta dermato-venereologica · 2024Article
- Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2023Article
- Recent advances in non-small cell lung cancer targeted therapy; an update review.Cancer cell international · 2023Review
- Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study.Investigational new drugs · 2023Observational
- Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.Cancer research and treatment · 2022Review
- Drug eruptions with novel targeted therapies - immune checkpoint and EGFR inhibitors.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2021Article
- Prognostic and predictive impact of creatine kinase level in non-small cell lung cancer treated with tyrosine kinase inhibitors.Translational lung cancer research · 2021Article
- [Generalized rash with osimertinib therapy for non-small cell bronchial carcinoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Article
- EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Herein, we describe the dAEs associated with third-generation EGFR-TKIs and our clinical experience with osimertinib, a third-generation EGFR-TKI approved by the U.S. Food and Drug Administration for the treatment of metastatic, IMPLICATIONS FOR PRACTICE: Appropriate prevention and management of dermatologic adverse events (dAEs) associated with the use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) may help patients to continue therapy and lessen any negative impact on their quality of life. EGFR-TKIs are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; however, dAEs associated with third-generation EGFR-TKIs are lower in frequency and severity. Before therapy, health care providers should discuss the potential osimertinib-associated dAEs and encourage patients to report their dAEs. Patients should also be educated on prophylactic measures to minimize the severity of dAEs and the importance of adherence to the treatment regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.